HTA Implementation Roadmap in Central and Eastern European Countries

Health Economics
Z KaloFinn Boerlum Kristensen

Abstract

The opportunity cost of inappropriate health policy decisions is greater in Central and Eastern European (CEE) compared with Western European (WE) countries because of poorer population health and more limited healthcare resources. Application of health technology assessment (HTA) prior to healthcare financing decisions can improve the allocative efficiency of scarce resources. However, few CEE countries have a clear roadmap for HTA implementation. Examples from high-income countries may not be directly relevant, as CEE countries cannot allocate so much financial and human resources for substantiating policy decisions with evidence. Our objective was to describe the main HTA implementation scenarios in CEE countries and summarize the most important questions related to capacity building, financing HTA research, process and organizational structure for HTA, standardization of HTA methodology, use of local data, scope of mandatory HTA, decision criteria, and international collaboration in HTA. Although HTA implementation strategies from the region can be relevant examples for other CEE countries with similar cultural environment and economic status, HTA roadmaps are not still fully transferable without taking into account country...Continue Reading

References

Nov 12, 2002·Journal of Health Services Research & Policy·Simon InnvaerAndrew Oxman
Nov 5, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J SchreyöggR Busse
Jul 8, 2008·International Journal of Technology Assessment in Health Care·Michael F DrummondSean D Sullivan
Jun 17, 2009·International Journal of Technology Assessment in Health Care·Rafał Nizankowski, Norbert Wilk
Jul 2, 2009·International Journal for Equity in Health·Boika RechelBernd Rechel
Jul 15, 2009·International Journal of Technology Assessment in Health Care·Jankauskiene Danguole
Nov 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael DrummondJohan Severens
Dec 25, 2009·International Journal of Technology Assessment in Health Care·Finn Børlum KristensenUNKNOWN European network for Health Technology Assessment (EUnetHTA)
Oct 15, 2010·The New England Journal of Medicine·Peter J Neumann, Milton C Weinstein
Oct 26, 2010·BMJ : British Medical Journal·Finn Børlum Kristensen, Ansgar Gerhardus
Mar 31, 2011·International Journal of Technology Assessment in Health Care·Joseph L Mathew
Aug 16, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Janneke P C GruttersManuela A Joore
Nov 3, 2011·ClinicoEconomics and Outcomes Research : CEOR·Tania StafinskiChristopher McCabe
May 24, 2012·International Journal of Technology Assessment in Health Care·Katarzyna Kolasa, Radek Wasiak
Jul 17, 2012·International Journal of Technology Assessment in Health Care·Chris HenshallLogan Mardhani-Bayne
Aug 24, 2012·Israel Journal of Health Policy Research·Jacob DreiherArnon D Cohen
Sep 4, 2012·Health Policy·Georgi IskrovRumen Stefanov
Oct 17, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sean R Tunis, Charles Turkelson
Nov 7, 2012·Health Policy·Piotr OzieranskiLawrence King
Nov 13, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mihajlo B Jakovljevic
Mar 14, 2013·The Laryngoscope·Luke Rudmik, Michael Drummond
Jun 14, 2013·International Journal of Technology Assessment in Health Care·Mirjana HuićClaudia Wild
Aug 21, 2013·Health Policy·Ruth LopertKalipso Chalkidou
Dec 3, 2013·International Journal of Technology Assessment in Health Care·Wija OortwijnLora Todorova
Jan 5, 2014·BMC Health Services Research·Kathryn OliverJames Thomas
Apr 30, 2014·International Journal of Technology Assessment in Health Care·Sergei MuratovJessie McGowan
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·László GulácsiNiek S Klazinga
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Márta PéntekLászló Gulácsi
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Imre BonczAndor Sebestyén
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Dóra EndreiIstván Agoston
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Felipe AdesMartine Piccart
Dec 19, 2014·Implementation Science : IS·Ties Hoomans, Johan L Severens
Nov 1, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·K GrzywaczA Zawada
Jan 1, 2013·Value in Health Regional Issues·Zoltán KalóUNKNOWN ISPOR Hungary Chapter

❮ Previous
Next ❯

Citations

Jun 5, 2016·Orphanet Journal of Rare Diseases·Tamás ZeleiZoltán Kaló
Oct 18, 2016·Frontiers in Public Health·Georgi IskrovRumen Stefanov
Jul 20, 2017·International Journal of Technology Assessment in Health Care·Iga LipskaAnke Hövels
Mar 27, 2018·Health Economics, Policy, and Law·Marcell CsanádiLawrence King
Dec 14, 2017·Journal of Health Services Research & Policy·Olga Löblová
Nov 15, 2017·BMC Health Services Research·Ali SafarnejadWim Groot
Feb 23, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·André Soares SantosCristina Mariano Ruas
Jan 31, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Patricia Vella BonannoBrian Godman
Aug 15, 2017·International Journal of Technology Assessment in Health Care·Mirjana HuicIvan Svajger
Apr 25, 2017·International Journal of Technology Assessment in Health Care·Valentina Prevolnik Rupel
Nov 3, 2017·International Journal of Technology Assessment in Health Care·Anna Zawada, Marjukka Mäkelä
Aug 2, 2017·International Journal of Technology Assessment in Health Care·Chara KaniPanagiota Litsa
Oct 5, 2019·International Journal of Technology Assessment in Health Care·Marcell CsanádiZoltán Kaló
Dec 8, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·András Inotai, Zoltán Kaló
Oct 5, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Ana V PejcicMihajlo Michael Jakovljevic
Apr 9, 2019·International Journal of Technology Assessment in Health Care·Wija Oortwijn, Philip Klein
Jun 10, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Matthew Kennedy-MartinKristina S Boye
Jun 6, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethZoltán Kaló
Apr 20, 2020·Value in Health Regional Issues·Ibrahim AlabbadiMuna Alshazili
Dec 20, 2017·Value in Health Regional Issues·Diego RosselliZoltán Kaló
May 21, 2021·Value in Health Regional Issues·Emad AlmomaniZoltán Kaló
Jan 22, 2019·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Finn Børlum KristensenAllan Wailoo
Oct 26, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Andrej JanezNataliya Zelinska

❮ Previous
Next ❯

Software Mentioned

Scopus
MCDA
EUnetHTA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.